TABLE 1.
Basic characteristics of included studies.
| Study ID | Sample size(E/C) | Age(year) | Male/Female | Intervention(s) | Comparators | Treatment duration(week) | With hypothyroidism | Outcomes | ||
|---|---|---|---|---|---|---|---|---|---|---|
| E | C | E | C | |||||||
| Zhang (2015) | 28/28 | 32.0 ± 5.2 | 3/53 | BLC 0.4g tid + LID | LID | 24 | not | ①②③④⑤ | ||
| Li et al. (2017) | 48/48 | 48 ± 5 | 24/24 | 25/23 | BLC 2.5g tid + LID | LID | 12 | not | ①②③④⑤ | |
| Zhu et al. (2020) | 30/30 | 35.07 ± 1.50 | 34.73 ± 1.45 | 0/30 | 0/30 | BLC 1.5g tid + LID | LID | 24 | not | ①②③④⑤ |
| Tan (2021) | 26/21 | 28.0 ± 5.7 | 6/41 | JSBC 1.5g tid + LID | LID | 28 | not | ①②③④⑤⑨ | ||
| Xue et al. (2021) | 40/40 | 41.47 ± 4.15 | 41.25 ± 4.13 | 20/20 | 18/22 | BLC 1.0g tid + LID | LID | 12 | not | ①③ |
| Aisha (2016) | 30/30 | 40.26 ± 8.17 | 40.71 ± 8.35 | 1/29 | 1/29 | BLC 2.5g bid + LT4 | LT4 | 24 | yes | ①②③④⑤ |
| He et al. (2016) | 39/17 | 41.40 ± 13.76 | 43.82 ± 12.48 | 11/28 | 7/10 | BLC 2.0g tid + LT4 | LT4 | 24 | yes | ①②③④⑤ |
| Yang et al. (2018a) | 35/30 | NA | NA | NA | BLC 2.0g tid + LT4 | LT4 | 24 | yes | ①②③④⑤⑨ | |
| Yang et al. (2018b) | 40/40 | 35.5 ± 9.8 | 35.9 ± 11.2 | 8/32 | 7/33 | BLC 3.0g tid + LT4 | LT4 | 24 | yes | ①②③④⑤⑨ |
| Kang and Piao (2019) | 35/35 | 47.14 ± 8.83 | 48.32 ± 9.12 | 3/32 | 5/30 | JSBC 0.99g tid + LT4 | LT4 | 24 | yes | ①②③④⑤⑥⑦⑨ |
| Bai et al. (2020) | 40/40 | 43.79 ± 3.46 | 43.68 ± 4.82 | 22/18 | 24/16 | JSBC 0.99g bid + LT4 | LT4 | 8 | yes | ①②③④⑤⑥⑧⑨ |
| Jin and Wang (2020) | 60/60 | 43.28 ± 6.87 | 22/98 | BLC 2.5g tid + LT4 | LT4 | 12 | yes | ①②③④⑤ | ||
| Wang et al. (2021) | 32/32 | 38.69 ± 7.88 | 37.85 ± 7.33 | 9/23 | 10/22 | BLC 2.5g tid + LT4 | LT4 | 12 | yes | ③④⑤ |
| Zhan and Chen (2021) | 40/40 | 32.56 ± 5.78 | 32.98 ± 3.01 | 11/29 | 13/27 | BLC 1.0g tid + LT4 | LT4 | 8 | yes | ①②③④⑤⑥⑦⑧⑨ |
E, experimental group; C, control group; BLC, bailing capsule; JSBC, jinshuibao capsule; LID, low-iodine diet; LT4, levothyroxine; ①free triiodothyronine (FT3); ②free thyroxine (FT4); ③thyroid stimulating hormone (TSH); ④thyroid peroxidase antibody (TPOAb); ⑤thyroglobulin antibody (TgAb); ⑥tumor necrosis factor alpha (TNF-α); ⑦interleukin-2 (IL-2); ⑧interleukin-6 (IL-6); ⑨adverse events.